Stem cell transplantation: progress in Asia

Lupus ◽  
2010 ◽  
Vol 19 (12) ◽  
pp. 1468-1473 ◽  
Author(s):  
L. Sun
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Stem Cell ◽  
Lupus Erythematosus ◽  
Systemic Lupus ◽  
Hematopoietic Stem ◽  
The Past ◽  
Complex Autoimmune Disease ◽  
Significant Mortality

Systemic lupus erythematosus (SLE) is a complex autoimmune disease with multiorgan involvement and high mortality, which was reduced because of the most widely and classically used immunosuppressive therapies. However, some patients continue to have significant mortality. So a shift in the approach to the treatment of SLE is needed. In the past decade, most transplants have been performed in the treatment of SLE with allogeneic or autologous hematopoietic stem cells and currently emerging mesenchymal stem cells. There are some important differences between the two procedures.

Treatment of Autoimmune Disease by Intense Immunosuppressive Conditioning and Autologous Hematopoietic Stem Cell Transplantation

Blood ◽  
1998 ◽  
Vol 92 (10) ◽  
pp. 3505-3514 ◽  
Author(s):  
Richard K. Burt ◽  
Ann E. Traynor ◽  
Richard Pope ◽  
James Schroeder ◽  
Bruce Cohen ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Multiple Sclerosis ◽  
Systemic Lupus Erythematosus ◽  
Stem Cells ◽  
Stem Cell ◽  
Autoimmune Disease ◽  
Hematopoietic Stem Cell Transplantation ◽  
Lupus Erythematosus ◽  
Systemic Lupus ◽  
Hematopoietic Stem

Multiple sclerosis, systemic lupus erythematosus, and rheumatoid arthritis are immune-mediated diseases that are responsive to suppression or modulation of the immune system. For patients with severe disease, immunosuppression may be intensified to the point of myelosuppression or hematopoietic ablation. Hematopoiesis and immunity may then be rapidly reconstituted by reinfusion of CD34+progenitor cells. In 10 patients with these autoimmune diseases, autologous hematopoietic stem cells were collected from bone marrow or mobilized from peripheral blood with either granulocyte colony-stimulating factor (G-CSF) or cyclophosphamide and G-CSF. Stem cells were enriched ex vivo using CD34+ selection and reinfused after either myelosuppressive conditioning with cyclophosphamide (200 mg/kg), methylprednisolone (4 g) and antithymocyte globulin (ATG; 90 mg/kg) or myeloablative conditioning with total body irradiation (1,200 cGy), methylprednisolone (4 g), and cyclophosphamide (120 mg/kg). Six patients with multiple sclerosis, 2 with systemic lupus erythematosus, and 2 with rheumatoid arthritis have undergone hematopoietic stem cell transplantation. Mean time to engraftment of an absolute neutrophil count greater than 500/μL (0.5 × 109/L) and a nontransfused platelet count greater than 20,000/μL (20 × 109/L) occurred on day 10 and 14, respectively. Regimen-related nonhematopoietic toxicity was minimal. All patients improved and/or had stabilization of disease with a follow-up of 5 to 17 months (median, 11 months). We conclude that intense immunosuppressive conditioning and autologous T-cell–depleted hematopoietic transplantation was safely used to treat these 10 patients with severe autoimmune disease. Although durability of response is as yet unknown, all patients have demonstrated stabilization or improvement.

Treatment of Autoimmune Disease by Intense Immunosuppressive Conditioning and Autologous Hematopoietic Stem Cell Transplantation

Blood ◽  
1998 ◽  
Vol 92 (10) ◽  
pp. 3505-3514 ◽  
Author(s):  
Richard K. Burt ◽  
Ann E. Traynor ◽  
Richard Pope ◽  
James Schroeder ◽  
Bruce Cohen ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Multiple Sclerosis ◽  
Systemic Lupus Erythematosus ◽  
Stem Cells ◽  
Stem Cell ◽  
Autoimmune Disease ◽  
Hematopoietic Stem Cell Transplantation ◽  
Lupus Erythematosus ◽  
Systemic Lupus ◽  
Hematopoietic Stem

Abstract Multiple sclerosis, systemic lupus erythematosus, and rheumatoid arthritis are immune-mediated diseases that are responsive to suppression or modulation of the immune system. For patients with severe disease, immunosuppression may be intensified to the point of myelosuppression or hematopoietic ablation. Hematopoiesis and immunity may then be rapidly reconstituted by reinfusion of CD34+progenitor cells. In 10 patients with these autoimmune diseases, autologous hematopoietic stem cells were collected from bone marrow or mobilized from peripheral blood with either granulocyte colony-stimulating factor (G-CSF) or cyclophosphamide and G-CSF. Stem cells were enriched ex vivo using CD34+ selection and reinfused after either myelosuppressive conditioning with cyclophosphamide (200 mg/kg), methylprednisolone (4 g) and antithymocyte globulin (ATG; 90 mg/kg) or myeloablative conditioning with total body irradiation (1,200 cGy), methylprednisolone (4 g), and cyclophosphamide (120 mg/kg). Six patients with multiple sclerosis, 2 with systemic lupus erythematosus, and 2 with rheumatoid arthritis have undergone hematopoietic stem cell transplantation. Mean time to engraftment of an absolute neutrophil count greater than 500/μL (0.5 × 109/L) and a nontransfused platelet count greater than 20,000/μL (20 × 109/L) occurred on day 10 and 14, respectively. Regimen-related nonhematopoietic toxicity was minimal. All patients improved and/or had stabilization of disease with a follow-up of 5 to 17 months (median, 11 months). We conclude that intense immunosuppressive conditioning and autologous T-cell–depleted hematopoietic transplantation was safely used to treat these 10 patients with severe autoimmune disease. Although durability of response is as yet unknown, all patients have demonstrated stabilization or improvement.

scholarly journals Improvement of systemic lupus erythematosus in dogs with canine adipose-derived stem cells

2019 ◽  
Vol 64 (No. 10) ◽  
pp. 462-466
Author(s):  
M Ko ◽  
TH Kim ◽  
Y Kim ◽  
D Kim ◽  
JO Ahn ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Stem Cells ◽  
Stem Cell ◽  
Cell Therapy ◽  
Stem Cell Therapy ◽  
Lupus Erythematosus ◽  
Adipose Derived Stem Cells ◽  
Systemic Lupus ◽  
Hind Limbs ◽  
Life Threatening

A 6-year-old, intact female, Maltese presented with limited movement of the hind limbs and intermittent pruritus for three months. The patient was diagnosed with systemic lupus erythematosus. Conventional immunosuppressive therapy was attempted for 70 days; however, the patient still suffered from life-threatening pancreatitis and hepatopathy. Therefore, we tried canine adipose-derived mesenchymal stem cells for immunomodulation and liver protection. After 6-months of the stem cell therapy, the patient’s walking and hepatopathy improved. These findings indicate that stem cell therapy may be another option for systemic lupus erythematosus in dogs.

Sign in / Sign up

Export Citation Format

Share Document